Soquelitinib

Soquelitinib (CPI-818) is Corvus Pharmaceuticals' oral covalent inhibitor of ITK, the kinase that fires up T cells when they see an antigen. Two programs matter: a Phase 2 in moderate-to-severe atopic dermatitis (SIERRA1, NCT07441395) [1] and a Phase 3 in relapsed/refractory peripheral T-cell lymphoma (NCT06561048) [2], the latter carrying FDA Fast Track [9] and Orphan Drug Designation [10]. The AD program is the commercial bet. Phase 1 Cohort 4 (200mg BID, n=12) returned EASI-75 in 75% of soquelitinib patients vs 40% placebo (n=10) at day 56, mean EASI reduction 72% vs 40% (p=0.035) [11][12] - numerically at or above dupilumab's Phase 3 EASI-75 of 44-52% at week 16 [13], with the standard caveat that small Phase 1 cohorts routinely compress in larger Phase 2/3 trials. If that signal holds, oral selective T-cell immunomodulation enters a market where Sanofi/Regeneron's injectable Dupixent did roughly $14B in 2024 sales across indications [8] and where JAK inhibitors carry black box warnings. The PTCL Phase 3 is the smaller but faster path to a label. Corvus held $236.7M cash as of 31 March 2026 with management-guided runway into Q2 2028 [14] - SIERRA1 will read out well inside the funded window. Watch SIERRA1 interim disclosures and PTCL Phase 3 progress over the next 12-18 months.

Pipeline drug. Soquelitinib has never been approved for any indication. Active programs span four trials: Phase 2 atopic dermatitis (SIERRA1, NCT07441395, n=200, recruiting, started Feb 2026, primary completion June 2027) [1]; Phase 3 relapsed/refractory peripheral T-cell lymphoma (NCT06561048, n=150, recruiting) [2]; Phase 1 atopic dermatitis safety/tolerability (NCT06345404, n=82, completed) [3] with positive Cohort 4 efficacy [11][12]; and a Phase 2 NIAID-sponsored study in autoimmune lymphoproliferative syndrome with FAS mutation (NCT06730126, n=15) [4]. The PTCL program holds FDA Fast Track Designation [9] and Orphan Drug Designation [10] - the latter providing 7-year US marketing exclusivity post-approval. No equivalent designations have been disclosed for the AD program. Cash position: $236.7M as of 31 March 2026, with management guidance of operations funded into Q2 2028 following a $189.4M financing in Q1 2026 [14] - this materially derisks the SIERRA1 readout from a dilution-overhang standpoint. Expected near-term catalysts: SIERRA1 interim or completion (12-week primary endpoint, primary completion guided to June 2027), ongoing PTCL Phase 3 enrollment progress, and ALPS-FAS readout. The 8-K cadence will telegraph timing - readouts always precede an 8-K, never lag.

ITK stands for interleukin-2-inducible T-cell kinase. It's an enzyme inside T cells that gets switched on when a T cell receptor sees its antigen - think of it as one of the wires that turns the T cell from idle to active. The biology that matters here: ITK is most important for Th2 cells, the T cell subset that drives the type 2 inflammation behind the itchy, oozing rash of atopic dermatitis. Knockout and inhibitor studies show that taking out ITK preferentially blunts Th2 responses while leaving anti-viral Th1 responses largely intact. That selectivity is the pitch - block ITK, dial down eczema-driving inflammation, avoid the broad immunosuppression of corticosteroids or the wider signaling shutdown of JAK inhibitors. Soquelitinib binds covalently to a cysteine on ITK and is selective within the Tec kinase family (which also includes BTK, the target of ibrutinib). Selectivity here is genuinely hard - most early ITK inhibitors hit BTK and other kinases too. The T-cell lymphoma rationale is different: many peripheral T-cell lymphomas depend on constitutive T-cell receptor signaling, so blocking ITK starves the malignant cells of growth signal. The ALPS-FAS rationale is different still: in ALPS, autoreactive T cells accumulate because defective FAS signaling prevents activation-induced cell death. ITK inhibition dampens the upstream TCR signaling that drives their chronic activation, reducing proliferation independent of the broken apoptosis pathway - the upstream brake substituting for the missing downstream one. A 2026 paper showed ITK inhibition also reshaped the T-cell compartment to improve anti-CD19 CAR-T efficacy [5], suggesting combination potential beyond monotherapy.

SIERRA1 (NCT07441395) enrolls 200 patients with moderate-to-severe atopic dermatitis randomized across four arms of 50 each: soquelitinib 200mg QD, 200mg BID, 400mg QD, and placebo, with 12-week treatment plus 90-day follow-up, primary endpoint percent change from baseline in EASI at week 12 [1]. The 200mg BID arm is the read-through arm given Cohort 4 in Phase 1 used that dose [11]; including both QD and BID arms is the right call for optimizing tolerability - chronic AD dosing rewards once-daily regimens. A 200-patient Phase 2 is sized correctly to read dose response and pick a Phase 3 dose, and EASI is the regulatory standard (dupilumab, abrocitinib, upadacitinib all built their approvals on EASI-based endpoints). The Phase 3 PTCL trial (NCT06561048) randomizes 150 patients with relapsed/refractory PTCL not otherwise specified, follicular helper T-cell lymphomas, or systemic anaplastic large-cell lymphoma 1:1 against investigator-choice standard of care, with progression-free survival as primary endpoint [2]. A 150-patient Phase 3 is feasible in a rare cancer where the SoC arm has historically delivered poor PFS, and Fast Track [9] should help the regulatory pathway. The NIAID-sponsored ALPS-FAS study (NCT06730126) is tiny (n=15) but mechanistically clean - a 25% reduction in spleen or target node volume at day 90 by CT/PET is an objective, hard-to-fake readout [4]. Two design concerns: SIERRA1 has no biomarker stratification for Th2-high patients, who would theoretically be most likely to respond; and the PTCL Phase 3 control arm is investigator's choice, which makes cross-trial comparison difficult.

Our model estimates a 6% chance this drug is eventually approved. That starting point comes from how often Phase 2 drugs in this area have historically reached approval - about 32% - but ten specific facts about this trial and sponsor push the number down. The biggest drags are heavier-than-usual blinding, the sponsor's thin or weak approval record, weak or limited earlier-phase results, and a randomized design. The remaining factors are close to average for this stage, so they don't move the estimate much either way.

Efficacy: Phase 1 Cohort 4 was n=12 active vs n=10 placebo - the signal is strong but the precision is wide. If Phase 2 EASI-75 lands materially below dupilumab's 44-52% week 16 bar [13], oral convenience alone will not unseat a $14B+ franchise [8]. Safety: ITK is required for normal anti-EBV T-cell responses, and ITK-deficient patients develop EBV-driven lymphoproliferation. The same mechanism that makes the PTCL program a credible antitumor strategy raises secondary malignancy concerns for chronic AD dosing - long-term extension data matters more than the headline 12-week EASI. The covalent BTK inhibitors (ibrutinib, acalabrutinib) showed off-target Tec kinase effects can cause atrial fibrillation and bleeding; soquelitinib is more selective, but the read-across risk is real and will be scrutinized. Execution: cash runway into Q2 2028 [14] removes the near-term dilution overhang that typically dogs single-readout small-caps - SIERRA1 will read out inside the funded window. IP runway is not disclosed in current filings and is a known gap for a small-cap with no approved drugs; readers should treat patent expiry as a material unknown. Commercial: dupilumab's dominance defines the AD bar; lebrikizumab, abrocitinib, upadacitinib, and an incoming wave of OX40-axis biologics all crowd the field. Payers will likely require step therapy through dupilumab. The PTCL program faces less competitive pressure but a smaller commercial pool - useful as a faster label, not as a primary value driver.

Worth watching, for two reasons: (1) Phase 1 Cohort 4 EASI-75 of 75% at day 56 is a real positive signal, not the absence of one - and the cash runway through 2028 means SIERRA1 reads out before financing pressure forces strategic shortcuts. (2) The PTCL program now has both Fast Track [9] and Orphan Drug Designation [10] - a 7-year exclusivity moat in a rare cancer is meaningful commercial real estate even on the smaller TAM. The signal moment is the SIERRA1 EASI readout (primary completion June 2027). Specific threshold that matters: EASI-75 at or above dupilumab's 44-52% Phase 3 benchmark at the 12-week primary endpoint, with no infection or malignancy signal, puts soquelitinib firmly in the conversation. Materially below 44% and the AD program is commercially difficult even if it clears regulatory bars. The Phase 3 PTCL program is the lower-headline-risk shot at a label - check back when interim PFS data emerges, likely 2027. Three concrete check-back triggers: (1) any 8-K disclosing additional Phase 1 AD long-term extension or durability data; (2) SIERRA1 interim dose-response disclosure; (3) PTCL Phase 3 enrollment milestones. The ALPS-FAS readout (NCT06730126) is the cleanest proof-of-mechanism if reported first - fifteen patients with hard imaging endpoints will tell you quickly whether ITK inhibition translates to T-cell suppression in humans.